I posted this yesterday but it seemed to have disappeared and hour later.
DNA executives at BIIB is not a new thing. They may be considering using Oceanside to produce more Rituxan for its ever increasing uses. BGEN had been working with DNA before it became BIIB on another class of immunosuppressives that may be getting closer to cllinical trials and need to produce drug for that--BIIB would benifit as does DNA. Maybe they were looking the place over but it doesn't mean a buy out--but then again it could.
McCamant writes that Biogen might be "an attractive take-over candidate" given its current valuation, and that Genentech (DNA) would be an "obvious suitor" because of its existing "co-promotion partnership" with Biogen for marketing Rituxan. Under such a deal, McCamant says that Genentech could capture 100 percent of U.S. sales for Rituxan and benefit from Biogen's additional manufacturing capacity. -- Ari Charney
Or will BIIB lease,sell & scrape to boost it's Stock price in hopes of more in a take/over. JMHO Gecko